Oncolytic Adenovirus Expressing Interferon YSCH-01 clinical trials
Also written YSCH-01.
How each study uses Oncolytic Adenovirus Expressing Interferon YSCH-01 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Oncolytic Adenovirus Expressing Interferon YSCH-01 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- YSCH-01
- 4
Studies by the year they started
4 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 4
Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) · Huashan Hospital (1) · Binhai Hospital of Fujian Medical University (1)
Often tested with
Tested in the same studies.
Izalontamab brengitecan (1) · CVL006 (1) · KXV01 (1) · MT027 (1) · QH101 (1) · META10 (1) · TAEST1901 (1) · TCN 201 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Oncolytic Adenovirus Expressing Interferon YSCH-01.
- Nov 2026Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent GlioblastomaEarly Phase 1 · Huashan Hospital
Studies
Open first, then newest update. How each study uses Oncolytic Adenovirus Expressing Interferon YSCH-01 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- YSCH-01 Via Nebulization in Pulmonary Metastasis of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC)RecruitingEarly Phase 1Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07793500Written as YSCH-01
- Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent GlioblastomaRecruitingEarly Phase 1Huashan HospitalNCT07538128Written as YSCH-01
- Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)Not yet recruitingPhase 1/2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07307053Written as YSCH-01
- Safety and Tolerability Study of Recombinant L-IFN Adenovirus Injection in Patients With Recurrent GlioblastomaRecruitingEarly Phase 1Binhai Hospital of Fujian Medical UniversityNCT05914935Written as Recombinant L-IFN adenovirus injection